– Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003 –

Ness Ziona, Israel – Nov. 13, 2020 – BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that phages identified by BiomX with a broad host range were able to target and eradicate 89 percent of distinct gut-harbored Klebsiella pneumoniae strains isolated from samples obtained from patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The study included over 1,000 strains isolated from over 300 patients with (IBD) or (PSC). In addition, oral administration of selected phage demonstrated efficacy in reducing target bacterial load in an in vivo model.

“These results support the potential of a phage therapy approach for the treatment of both IBD and PSC, demonstrating the ability to identify and select phage with direct relevance to patients,” commented Eran Elinav, M.D., Ph.D., Professor in the Department of Immunology at the Weizmann Institute of Science, a scientific founder of BiomX and a scientific advisor. “Our analysis of these results has informed the design and broad host range of BX003, an orally delivered candidate phage therapy targeting Klebsiella pneumoniae for the treatment of both IBD and PSC.“

The results will be featured in a poster presentation at The Liver Meeting® 2020, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Nov. 13-16, 2020. Presentation details are as follows:

Title: Broad Host Range Bacteriophage for Reduction of Klebsiella Pneumoniae as Potential Therapy in Primary Sclerosing Cholangitis (PSC) (Poster #1230)

Lead Author: Maya Kahan-Hanum, Ph.D., BiomX

Presentations will be available at the Company’s website at https://www.biomx.com/publications-2/.

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, colorectal cancer, and cystic fibrosis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com.

Safe Harbor Language 

This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when this press release discusses the potential of a phage therapy approach for treatment of certain medical conditions and the ability to identify and select phage with direct relevance to patients, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, invest should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and additional disclosures BiomX makes in its filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

###

Contacts
Noel Kurdi, BiomX
VP Investor Relations and Strategy
(646) 241-4400
noelk@biomx.com

Media contact:
Rich Allan, Solebury Trout
(646) 378-2958
rallan@soleburytrout.com